Abstract
..
Main
..
RCT vs. Obs.
..
Feedback
Home
c19early.org COVID-19 treatment researchMontelukastMontelukast (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
 
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Montelukast reduces COVID-19 risk: real-time meta analysis of 9 studies

@CovidAnalysis, December 2024, Version 9V9
Post
Share
PDF
Studies
Feedback
https://c19early.org/mkmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Excluded Lima-Morales 78% 0.22 [0.12-0.41] death 15/481 52/287 CT​1​ Improvement, RR [CI] Treatment Control Excluded Lima-Morales 52% 0.48 [0.20-1.18] ventilation 8/434 11/287 CT​1​ Excluded Lima-Morales 67% 0.33 [0.22-0.47] hosp. 44/481 89/287 CT​1​ Excluded Lima-Morales 59% 0.41 [0.30-0.55] no recov. 75/481 118/287 CT​1​ Khan 64% 0.36 [0.10-1.03] progression 3/30 20/62 Khan 12% 0.88 [0.67-1.14] hosp. time 30 (n) 62 (n) Kumar (DB RCT) 67% 0.33 [0.04-3.09] ICU 1/45 3/45 Kumar (DB RCT) -25% 1.25 [0.54-2.87] progression 10/45 8/45 Kumar (DB RCT) 0% 1.00 [0.64-1.56] no disch. 21/45 21/45 Kerget (RCT) 92% 0.08 [0.01-0.56] death 0/120 4/60 Kerget (RCT) 89% 0.11 [0.01-2.02] death 0/60 4/60 Kerget (RCT) 89% 0.11 [0.01-2.02] death 0/60 4/60 Kerget (RCT) 81% 0.19 [0.05-0.68] progression 3/120 8/60 Kerget (RCT) 88% 0.12 [0.02-0.97] progression 1/60 8/60 Kerget (RCT) 75% 0.25 [0.06-1.13] progression 2/60 8/60 Kerget (RCT) 15% 0.85 [0.72-0.99] hosp. time 60 (n) 60 (n) Kerget (RCT) 15% 0.85 [0.74-0.99] hosp. time 60 (n) 60 (n) Soltani (RCT) 20% 0.80 [0.67-0.95] hosp. time 51 (n) 76 (n) Soltani (RCT) 25% 0.75 [0.64-0.88] no recov. 51 (n) 76 (n) Soltani (RCT) 21% 0.79 [0.62-1.02] no recov. 51 (n) 76 (n) Mohamed H.. (RCT) 50% 0.50 [0.41-0.61] recov. time 32 (n) 36 (n) post-COVID cough Mohamed H.. (RCT) 70% 0.30 [0.22-0.41] recov. time 32 (n) 36 (n) post-COVID cough Mohamed H.. (RCT) 82% 0.18 [0.11-0.30] recov. time 32 (n) 36 (n) post-COVID cough Mohamed H.. (RCT) 80% 0.20 [0.12-0.32] recov. time 32 (n) 36 (n) post-COVID cough Mohamed H.. (RCT) 82% 0.18 [0.11-0.30] recov. time 32 (n) 36 (n) post-COVID cough ACTIV-6 Rothman (DB RCT) 1% 0.99 [0.14-7.01] hosp. 2/628 2/622 ACTIV-6 Rothman (DB RCT) 1% 0.99 [0.52-1.89] hosp./ER 18/628 18/622 ACTIV-6 Rothman (DB RCT) -48% 1.48 [0.33-2.96] progression n/a n/a ACTIV-6 Rothman (DB RCT) 29% 0.71 [0.16-1.49] progression n/a n/a ACTIV-6 Rothman (DB RCT) -31% 1.31 [0.50-2.29] progression n/a n/a ACTIV-6 Rothman (DB RCT) 2% 0.98 [0.89-1.10] no recov. 628 (n) 622 (n) ACTIV-6 Rothman (DB RCT) 16% 0.84 [0.68-1.05] no recov. 186 (n) 183 (n) ACTIV-6 Rothman (DB RCT) 3% 0.97 [0.83-1.14] no recov. 341 (n) 337 (n) ACTIV-6 Rothman (DB RCT) -37% 1.37 [0.49-3.85] no recov. 10 (n) 13 (n) ACTIV-6 Rothman (DB RCT) -614% 7.14 [3.85-14.3] no recov. 186 (n) 183 (n) ACTIV-6 Rothman (DB RCT) 2% 0.98 [0.96-1.00] recov. time 628 (n) 622 (n) Zengin 14% 0.86 [0.21-3.57] death 3/35 4/40 Zengin -90% 1.90 [0.49-7.40] ICU 5/35 3/40 Zengin 3% 0.97 [0.75-1.25] hosp. time 35 (n) 40 (n) Bozek 91% 0.09 [0.01-0.80] hosp. 1/327 4/118 Bozek 82% 0.18 [0.06-0.59] cases 4/327 8/118 Alhmoud 13% 0.87 [0.52-1.47] hosp. 111 (n) 505 (n) Montelukast COVID-19 outcomes c19early.org December 2024 ​1​ CT: study uses combined treatment Favors montelukast Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0